Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Selling drying up, strangely. Some people must be banking on the rejection of the POR and a resulting spike.
There is a hearing today to cover pretty much any remaining business. We should have an idea of the viability/finality of the POR after that.
Weird...TDA ticker jumped from 600k to 4.3MM. It's back to normal now.
Uhh...did somebody just buy 3.5MM shares?
The point is: if you're implying that nothing new, important, or otherwise of considerable value to shareholders can be discussed on the conference call, then you're wrong.
If you're saying that you doubt it, fine, but stop trying to imply that you know it can't happen because of your deep understanding of regulations.
This isn't even remotely true. Tons of material events for major companies have been announced via conference call or webcast/presentation.
Given the pace of revenue versus operating costs and capital investments, everyone already know that the company would have to recapitalize before achieving future profitability. I would guess that something like an expectation of dilution up to 25% was already baked into the PPS. This deal qualifies as slightly better than expectation, and I think this will turn out to be an excellent investment for anyone with the patience to actually hold for 18+ months.
Huh, someone actually bought some ILNS today. Obviously tiny in terms of dollar value, but more activity than we've seen around here in a long time.
At this point we're awaiting news about the delayed contract decisions.
This is definitely starting to feel like the end.
No active trials, no news, no funds to finance discovery and zero demand to raise future capital. There is pretty much no hope outside of something extremely unexpected happening or liquidation of the IP, if that has any value anymore. I'm tempted to cash in while it's still between .02 and .05, which is probably way above the fair market value.
I think most of us are patiently awaiting the annual report before commenting.
Shouldn't the 10-Q have been submitted already?
I don't know. The 1-share trade this morning is a reminder that there are still people trying to paint that picture and get in on the cheap.
Yeah, but they need to turn that IP into $ or we're all here for nothing.
Hey, at least they consider it to be worth money!
Why are people acting like this is some huge dump? Less than $15K traded today.
I think the IP still has value but time is running out for a company with no cash flow. There is going to have to be a fire sale at some point.
So basically the Phase 1 didn't yield significant changes from a treatment standpoint, but I don't think that's too unexpected. As long as the drug is well tolerated they can try new doses and delivery techniques in subsequent phases if they still think it has promise. Treatment was only a secondary measure.
Still, my hope is that ILNS was waiting to hear about this trial just in case there was something significant enough to seek orphan designation and holding off on a sale based on that timing. But we'll just have to wait and see.
All in all, not good news, but not really bad news either.
Not very promising BUT there's always a chance that there's a deal in place that was waiting for the current trials to wrap up before executing.
Well the Shire trial is still active and those results were available last summer, so I'm not ready to jump ship.
http://www.pfizer.com/research/science_and_technology/product_pipeline
You can read it in the pdf or just click on the discontinued tab. Either way, it says ponz for CAA discontinued.
Pfizer pipeline update shows ponezumab for CAA discontinued.
Nothing new in the Shire report, but Pfizer's Q1 will be out tomorrow. If results of the ponezumab CAA analysis are ready and interesting enough they could be included.
Are you going to explain what this has to do with ILNS?
That would be a valuation in the $75-$100MM range, which definitely isn't absurd.
At the very least, this should fund operations through July, which is the deadline for Shire posting trial results.
Good catch. I hope they're anticipating a liquidity event. Lord knows I am.
Should be getting close to quarterly pipeline updates from our two big pharma friends.
I don't think they have a patent on the compound, but they have one on "methods of treatment for taupathies" which includes just about every possible use case for ponezumab. So, I think they still have a patent claim.
...according to whom?
Busy day here: one share traded.
Relax. It will take the market a little while to digest this information.
Reading some articles this week and it seems that the CAA community is very high on ponezumab as a potential treatment. Every single article on emerging treatments has the ponz study as number one of their list. I'm doubting that Pfizer sits on results for a year with the level of interest and scrutiny that study is getting.
Unusually light activity pre-market.
Nothing new, but thank you for the DD. If anything, Shire is moving at your typical corporate pace in making decisions about it, but it's at least a good sign that the trial ended 10 months ago and they still consider it part of the pipeline.
Personally I think the recent activity coincides more suspiciously with the wrapping up of the Prizer ponezumab trial for CAA. I'm guessing we hear something about that trail in the next month or two.
How long does the orphan drug designation process typically take?
And some institution with 15MM to spare was waiting to pick it all up.
I don't think you get to just stop operating the business once you're in buyout conversations.
If they had already come to a deal, we would have heard. Right now we only speculate that they are shopping/considering it.
So, I don't think this news affects the possibility whatsoever.
It's majority owned by private equity already.
Aren't you just describing what being long on a stock is? You wait until it realizes its potential value. It can be frustrating, but only if you expect things to play out in the short-term.